A sterile parenteral dosage form for neonatal calf enteric septicaemia is manufactured by aseptic dissolution of mecillinam veterinary grade API in deoxygenated Water for Injections, followed by sterilising filtration and aseptic filling into Type I glass vials. Because the beta-lactam ring of amdinocillin is susceptible to hydrolytic ring-opening in aqueous media, terminal moist-heat sterilisation is not assigned as the primary sterilisation step; a 0.22 µm polyethersulfone sterilising-grade filter is integrity-tested by bubble point or forward flow before use. A 50 mg/mL solution requires 5.0% w/v mecillinam on anhydrous basis, with 0.85% w/v sodium chloride for isotonicity and a phosphate buffer adjusted to pH 6.2–6.8. Dissolution is performed in a jacketed vessel held at 15–25°C under nitrogen overlay, with dissolved oxygen reduced to < 0.5 mg/L by sparging. The maximum acceptable hold time between dissolution and filling is 4 h; batches exceeding this interval are rejected due to pH drift and related ring-opening degradation. Filling is carried out on a peristaltic aseptic filling line with in-line filter differential pressure maintained below 1.5 bar and headspace oxygen in sealed vials controlled to < 2.0% v/v. Compliance is structured around EU GMP Annex 1 for sterile manufacture, Ph. Eur. 2.6.1 Sterility, Ph. Eur. 5.1.1 Methods of preparation of sterile products, Ph. Eur. 3.2.1 Glass containers for pharmaceutical use, VICH GL18 residual solvents in veterinary medicinal products, and Regulation (EU) 2019/6 for veterinary medicinal product authorisation. For food-producing species, maximum residue limit status must be confirmed under Regulation (EU) No 37/2010 before injection in calves intended for human consumption. Terminal product types include 50 mL, 100 mL, and 250 mL single-dose vials of refrigerated solution, as well as lyophilised powder for reconstitution in 10 mL diluent for intramuscular or slow intravenous use under veterinary supervision. Published stability data specific to mecillinam veterinary injectable formulations stored for 12 months at 2–8°C are limited; manufacturers must generate real-time stability data as part of the marketing authorisation dossier.

Why Does Drinking-Water Soluble Powder for Broiler Enteric Colibacillosis Need Low-Dewpoint Blending?

Oral water-soluble powder for broiler flocks is formulated as a free-flowing admixture of mecillinam and an anhydrous carrier system because the beta-lactam hygroscopicity and hydrolysis profile force stringent environmental control during dry blending. The formulation addition ratio is calculated from the target drinking-water concentration: a 100 g sachet with 10.0% w/w active content delivers approximately 100 mg/L when added to 1000 L of drinking water. In field proportionality, active content may range from 5.0% to 20.0% w/w depending on stock solution protocols and proportioner settings. Blending is performed in a tumble blender at 60% vessel capacity, 18 rpm, for 25 min, with ambient relative humidity held below 40% RH and room temperature at 20–25°C. Pre-sifting through a 500 µm mesh removes agglomerates before blending, and the finished powder is filled into aluminium-polyethylene laminate sachets with desiccant to maintain headspace moisture below 5.0% w/w. The process conflict is that once dissolved, mecillinam activity decays in warm, contaminated farm water; therefore the dry product must remain free-flowing, low-moisture, and rapidly soluble without generating dust. Powder batches should not be blended at RH > 60% without pre-dried carrier and desiccated final packaging. Compliance for this non-sterile dosage form is anchored to Ph. Eur. 5.1.4 Microbial quality of non-sterile products, Ph. Eur. 2.9.40 Uniformity of dosage units for single-dose sachets, CLSI VET01S susceptibility breakpoints for avian Escherichia coli, and Regulation (EU) 2019/6 for national authorisation of a drinking-water antibiotic in food-producing poultry. Terminal product types include 100 g, 500 g, and 1 kg laminate sachets, plus 25 kg bulk drums for automated proportioning systems in poultry houses. Published data for mecillinam stability in drinking water at 100 mg/L under farm conditions are limited, so the reconstituted solution should be consumed within 6 h and not exposed to direct sunlight or alkaline water above pH 8.

Low-dust medicated premix for swine enteric colibacillosis is produced by top-spray fluid-bed granulation of mecillinam onto a porous carrier, with active content adjusted to deliver a defined in-feed concentration. A 5.0% w/w premix incorporated at 4.0 kg per tonne of finished feed yields 200 mg active per kg feed; lower dosages are calculated proportionally from the prescribed mg/kg bodyweight regimen and daily feed intake. Granulation uses a top-spray fluid-bed dryer with inlet air temperature 60°C, product temperature 30–35°C, spray rate 40–80 g/min, and final loss on drying below 2.5% w/w. Mecillinam is dispersed in purified water adjusted to pH 6.5 as the granulation binder; binder pH below 4 or above 8 is avoided because the beta-lactam ring undergoes accelerated hydrolysis outside the neutral window. The main process conflict is beta-lactam cross-contamination in non-target feed batches; a validated cleaning sequence with 0.1 M sodium hydroxide solution followed by hot water at 80°C is used before and after the campaign, with analytical swab sampling for beta-lactam residues. Compliance references Ph. Eur. 5.1.4 Microbial quality of non-sterile products, Regulation (EU) 2019/6, and national residue surveillance schemes for food-producing swine where an MRL has been assigned under Regulation (EU) No 37/2010. Terminal product types include 5.0% w/w and 10.0% w/w medicated premixes in 20 kg multi-wall bags, intended for licensed feed-mill dilution into finished pig feed. The formulation must not be combined with amine-based additives or strongly alkaline feed buffers, as primary amines accelerate beta-lactam degradation and reduce active recovery in finished feed assays.

Companion Animal Urinary Tract Tableting: Compaction and Dissolution Limits

Direct compression of mecillinam tablets for canine and feline urogenital Escherichia coli is constrained by poor API flow, high dose variability, and the need to maintain dissolution without exposing the beta-lactam to excessive moisture. A representative 100 mg tablet is produced at total mass 400 mg, with API content 25.0% w/w, microcrystalline cellulose 50.0% w/w, lactose monohydrate 23.25% w/w, crospovidone 1.0% w/w, and magnesium stearate 0.75% w/w. Blending is performed in a bin blender at 10 rpm for 20 min, followed by compression on a rotary tablet press fitted with 8.0 mm round biconvex punches. Compaction force is maintained between 8 kN and 15 kN; force above 15 kN produces capping and lamination due to low API compressibility, while force below 8 kN yields friability above the acceptance limit. Target tablet hardness is 60–100 N, friability is controlled to < 1.0% according to Ph. Eur. 2.9.7, and dissolution is tested at 50 rpm paddle speed in 0.1 M hydrochloric acid at 37°C with Q = 80% at 30 min per Ph. Eur. 2.9.3. Compliance is supported by Ph. Eur. 2.9.40 Uniformity of dosage units, Ph. Eur. 5.1.4 Microbiological quality of non-sterile products, CLSI VET01S susceptibility breakpoints for canine and feline urinary E. coli isolates, and national prescribing laws for companion animal veterinary medicines. Terminal product types include 50 mg, 100 mg, and 200 mg film-coated tablets in PVC/PVDC/aluminium blister packs. Published data for mecillinam tablet bioavailability in cats and dogs are limited; administration should be based on culture-confirmed susceptibility and veterinary extrapolation from human amdinocillin pharmacokinetic data rather than empirical prescribing.

Oral Granules for Equine Neonatal Enteric Infections Require Intraluminal Retention of the Amdinocillin Moiety

Oral granules for foals with Gram-negative enteritis are prepared by wet granulation to produce discrete particles that release mecillinam in the intestinal lumen, where local activity against Escherichia coli is required rather than systemic absorption of the non-esterified amdinocillin molecule. A 250 mg/g granule is formulated with mecillinam 25.0% w/w, lactose monohydrate and microcrystalline cellulose as diluents, and hydroxypropyl methylcellulose as binder. The binder solution is purified water adjusted to pH 6.5, and the wet mass is produced in a high-shear granulator at impeller speed 200 rpm and chopper speed 1500 rpm, with binder addition of 8.0%–12.0% w/w. The wet granules pass through a 1.0 mm screen and are dried in a fluid-bed dryer at 40°C to final loss on drying < 2.5% w/w. Final granules are sieved to a particle-size distribution between 100 µm and 1.0 mm according to Ph. Eur. 2.9.38. This formulation is not enteric-coated because intraluminal action is intended; an enteric coating would delay release beyond the target proximal intestinal segment and reduce local drug concentration at the infection site. Compliance is anchored to Ph. Eur. 5.1.4 Microbial quality of non-sterile products, Ph. Eur. 2.9.38 Particle-size distribution estimation by analytical sieving, VICH GL18 residual solvents, and national equine veterinary prescribing rules where such use falls under the prescribing cascade. Terminal product types include 10 g and 25 g single-dose sachets and unit-dose oral syringes for foal administration. Published data for this specific equine indication are limited; manufacturers must verify active recovery in finished granules and avoid storage above 25°C or RH > 60% to prevent beta-lactam hydrolysis before administration.

Hard gelatin capsule dosage forms containing mecillinam for companion animal Escherichia coli cystitis are manufactured by dry blending followed by high-speed capsule filling, with strict control of fill weight and content uniformity because the API is typically present at low unit dose. A 50 mg capsule at total fill 200 mg contains mecillinam 25.0% w/w, lactose monohydrate 73.0% w/w, magnesium stearate 1.0% w/w, and colloidal silicon dioxide 1.0% w/w. Blending is conducted in a bin blender at 10 rpm for 20 min, and the mixture is filled into size 2 hard gelatin capsules on a dosator or screw-feed capsule filling machine targeting fill weight 200 mg ± 3.0%. In-process controls include content uniformity according to Ph. Eur. 2.9.40 at start, middle, and end of filling, final powder moisture below 5.0% w/w, and capsule disintegration testing according to Ph. Eur. 2.9.1. Compliance is structured around Ph. Eur. 5.1.4 Microbiological quality of non-sterile products, EU GMP Annex 1 only where relevant to the antimicrobial containment suite, CLSI VET01S susceptibility breakpoints for canine and feline urinary isolates, and national prescribing requirements for companion animal antimicrobials. Terminal product types include 50 mg and 100 mg capsules in PVC/PVDC/aluminium blister strips. Published data for mecillinam capsule bioavailability in cats are limited; capsule administration should be reserved for susceptibility-confirmed urinary tract infection under veterinary supervision, and the formulation must not be transitioned to a prodrug salt without separate pharmacokinetic justification.